Cyclo Therapeutics, Inc. Warrant
CYTHW
CYTHW was delisted on the 25th of March, 2025.
3 hedge funds and large institutions have $1.66K invested in Cyclo Therapeutics, Inc. Warrant in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
37% more capital invested
Capital invested by funds: $1.21K → $1.66K (+$449)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$28 |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $1.64K | +$16 | +100 | +0.9% |
|
|
2
UBS Group
Zurich,
Switzerland
| $13 | +$28 | +175 | New |
|
|
3
Bank of America
Charlotte,
North Carolina
| $12 | +$3 | +16 | +11% |
|
CYTHW Hedge Fund Activity: Q4 2024 in Review
3 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Warrant (CYTHW) for Q4 2024, worth a combined $1.66K — up 37% from $1.21K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CYTHW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $28.
- 3 institutional investors held Cyclo Therapeutics, Inc. Warrant (CYTHW) as of Q4 2024, up from 2 in Q3 2024.
- Funds reported $1.66K of Cyclo Therapeutics, Inc. Warrant stock for Q4 2024, up 37% quarter-over-quarter.
- 1 fund opened new Cyclo Therapeutics, Inc. Warrant positions in Q4 2024 and 0 closed out, a net change of +1 holder.
- The largest Cyclo Therapeutics, Inc. Warrant buyer in Q4 2024 was UBS Group, an estimated $28 added.
Based on aggregated 13F filings for Q4 2024.